PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery-Reference-Cited by-同舟云学术

PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery

Published:2018-02-23 Issue:4 Volume:40 Page:1700247
ISSN:0265-9247
Container-title:BioEssays
language:en
Short-container-title:BioEssays

Author:

Gu Shanshan¹²,Cui Danrui¹²,Chen Xiaoyu¹²,Xiong Xiufang¹²,Zhao Yongchao¹²

Affiliation:

1. Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine; 310003 Hangzhou China

2. Institute of Translational Medicine, Zhejiang University School of Medicine; Hangzhou China

Funder

National Key R&D Program of China

Natural Science Foundation of Zhejiang Province

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Biochemistry, Genetics and Molecular Biology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bies.201700247/fullpdf

Reference69 articles.

1. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

2. Waste disposal—An attractive strategy for cancer therapy

3. Induced protein degradation: an emerging drug discovery paradigm

4. Multiplex Genome Engineering Using CRISPR/Cas Systems

5. Off-target effects by siRNA can induce toxic phenotype

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy;Bioorganic & Medicinal Chemistry;2024-10

2. A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy;Nano Research;2024-09-07

3. Cullin-RING Ligase 4 in Cancer: Structure, Functions, and Mechanisms;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. PROTAC: Novel degradable approach for different targets to treat breast cancer;European Journal of Pharmaceutical Sciences;2024-07

5. Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer;Current Signal Transduction Therapy;2024-07